- Siemens Healthineers reported a 1Q adjusted EBIT of €822 million, an 11% increase year over year, exceeding the €803.3 million estimate.
- Imaging segment’s adjusted EBIT rose 6% to €565 million, surpassing the €560.6 million prediction.
- Diagnostics segment achieved a 54% growth in adjusted EBIT, reaching €83 million, compared to an expected €73.1 million.
- Advanced Therapies adjusted EBIT was €70 million, slightly under the €72.7 million estimate but up 2.9% year over year.
- Total revenue saw a 5.9% increase, amounting to €5.48 billion, beating the expected €5.36 billion.
- Imaging sales climbed 7.9% to €3.01 billion, outpacing the €2.89 billion forecast.
- Advanced Therapies sales increased by 5.1% to €499 million, slightly above the €495.3 million estimate.
- Diagnostics sales were €1.07 billion, a modest 0.9% growth, but slightly below the €1.08 billion estimate.
- Earnings per share (EPS) stood at €0.42, up from €0.39 year over year, and higher than the forecasted €0.40.
- Adjusted EBIT margin rose to 15%, compared to 14.3% in the previous year.
- Adjusted EPS increased to €0.51, surpassing the estimated €0.48.
- Free cash flow surged to €810 million, a significant gain from €238 million year over year.
- Varian sales reached €974 million, a 6.9% rise, exceeding the €953.1 million estimate.
- Varian’s adjusted EBIT was €166 million, marking a 14% increase, above the €155.4 million expectation.
- Siemens Healthineers maintained its full-year forecast of 5% to 6% comparable sales growth, close to the 5.24% anticipated growth.
- Adjusted EPS guidance for the year remains between €2.35 and €2.50, with market estimates at €2.46.
- The Americas region experienced significant revenue growth, while the Asia Pacific Japan region saw very strong growth.
- EMEA region’s revenue was flat after notable growth in the previous year, while China’s revenue declined mid-single-digit due to order delays.
“`
A look at Siemens Healthineers Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Siemens Healthineers, a leading medical technology company, appears to have a positive long-term outlook based on the Smartkarma Smart Scores. With strong scores in Growth and Momentum, it indicates that the company is likely to experience robust expansion and market momentum in the future. Additionally, its moderate scores in Dividend and Resilience suggest a stable financial performance and ability to withstand economic challenges.
Siemens Healthineers operates globally, offering a wide range of cutting-edge medical imaging and diagnostics solutions. These technologies play a crucial role in the healthcare industry, positioning the company well for continued growth and innovation in the years ahead.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
